OPRX vs. ZFOX, DHX, STCN, RMNI, EGIO, MCHX, EEX, RGP, ZH, and GRVY
Should you be buying OptimizeRx stock or one of its competitors? The main competitors of OptimizeRx include ZeroFox (ZFOX), DHI Group (DHX), Steel Connect (STCN), Rimini Street (RMNI), Edgio (EGIO), Marchex (MCHX), Emerald (EEX), Resources Connection (RGP), Zhihu (ZH), and Gravity (GRVY). These companies are all part of the "business services, not elsewhere classified" industry.
OptimizeRx (NASDAQ:OPRX) and ZeroFox (NASDAQ:ZFOX) are both small-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.
OptimizeRx presently has a consensus target price of $15.86, indicating a potential upside of 52.18%. ZeroFox has a consensus target price of $3.50, indicating a potential upside of 209.73%. Given ZeroFox's higher possible upside, analysts plainly believe ZeroFox is more favorable than OptimizeRx.
OptimizeRx has higher earnings, but lower revenue than ZeroFox. OptimizeRx is trading at a lower price-to-earnings ratio than ZeroFox, indicating that it is currently the more affordable of the two stocks.
OptimizeRx has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, ZeroFox has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500.
In the previous week, OptimizeRx had 1 more articles in the media than ZeroFox. MarketBeat recorded 5 mentions for OptimizeRx and 4 mentions for ZeroFox. ZeroFox's average media sentiment score of 1.13 beat OptimizeRx's score of 0.48 indicating that ZeroFox is being referred to more favorably in the news media.
76.5% of OptimizeRx shares are held by institutional investors. Comparatively, 37.3% of ZeroFox shares are held by institutional investors. 4.4% of OptimizeRx shares are held by insiders. Comparatively, 12.8% of ZeroFox shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
OptimizeRx has a net margin of -24.56% compared to ZeroFox's net margin of -152.73%. OptimizeRx's return on equity of -7.72% beat ZeroFox's return on equity.
OptimizeRx received 138 more outperform votes than ZeroFox when rated by MarketBeat users. Likewise, 62.83% of users gave OptimizeRx an outperform vote while only 44.44% of users gave ZeroFox an outperform vote.
Summary
OptimizeRx beats ZeroFox on 13 of the 18 factors compared between the two stocks.
Get OptimizeRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptimizeRx Competitors List
Related Companies and Tools
